Showing 5081-5090 of 5621 results for "".
- New Hope for Patients With Vision Loss at SAVIR-Center for Vision Restorationhttps://modernod.com/news/new-hope-for-patients-with-vision-loss-at-savir-center-for-vision-restoration/2477031/Persistent psychological stress, which is widely recognized as a consequence of vision loss, is also a major contributor to its development and progression, according to a study published in the EPMA Journal, the official journal of the European Association for Predictive, Preventive, and
- Wolfgang Haigis—Scientist Known for His Formulae—Dies at 72https://modernod.com/news/wolfgang-haigis-scientist-known-for-his-formulae-dies-at-72/2477025/The German Society for Cataract and Refractive Surgery (DGII) has announced that Prof. Dr. Wolfgang Haigis, a physicist working at the University of Wurzburg, died on October 15 at the age of 72. Dr. Haigis was a pioneer and a driving force in the development and the refinement of biometry
- Sleep Apnea Linked to Blinding Eye Disease in People with Diabeteshttps://modernod.com/news/sleep-apnea-linked-to-blinding-eye-disease-in-people-with-diabetes/2477016/New research from Taiwan shows that severe sleep apnea is a risk factor for developing diabetic macular edema, a complication of diabetes
- Using AI to Screen for Diabetic Eye Disease Feasible in the Real Worldhttps://modernod.com/news/using-ai-to-screen-for-diabetic-eye-disease-feasible-in-the-real-world/2477017/New research shows that an automated, artificial intelligence (AI) screening system accurately detects diabetic retinopathy 95.5 percent of the time. The system doesn’t require the input of an expert ophthalmologist and it can provide a reading in 60 seconds, making real-time screening possible f
- Eyevance Pharmaceuticals Acquires Tobradex ST and Natacynhttps://modernod.com/news/eyevance-pharmaceuticals-acquires-tobradex-st-and-natacyn/2477011/Eyevance Pharmaceuticals has announced the acquisition of Tobradex ST (tobramycin/dexamethasone ophthalmic suspension) 0.3%/0.05% and Natacyn (natamycin ophthalmic suspension) 5% from Novartis. Terms of the deal were not disclosed. “The acquisition of Tobradex ST and Natacyn further
- Luneau Technology Acquires Next Sight to Enter Telehealth Markethttps://modernod.com/news/luneau-technology-acquires-next-sight-to-enter-telehealth-market/2477007/Luneau Technology group announced that it has acquired Padova, Italy-based Next Sight, maker of the Nexy retinal screening device. Terms of the deal were not disclosed. The acquisition brings to Luneau increased capabilities–covering both back and front of the eye. Luneau develops,
- Antibody-based eye drops show promise for treating dry eye diseasehttps://modernod.com/news/antibody-based-eye-drops-show-promise-for-treating-dry-eye-disease/2477005/Researchers at the University of Illinois at Chicago are the first to identify the presence of a specific type of antibody, called anti-citrullinated protein autoantibodies, or ACPAs, in human tear fluid. They are also the first to demonstrate that patients with dry eye d
- AAO: In-Office Gene Therapy for Wet AMD is Cominghttps://modernod.com/news/aao-in-office-gene-therapy-for-wet-amd-is-coming/2477002/Gene therapy is showing promise for one of the most common causes of blindness. Data presented on Friday show that six patients with wet age-related macular degeneration (AMD) have, so far, an average of 8 months without the need for continued injections to control a di
- Kodiak Sciences Announces Data from Ongoing Phase 1b Study of KSI-301 in Patients With Wet AMD, DME and RVOhttps://modernod.com/news/kodiak-sciences-announces-data-from-ongoing-phase-1b-study-of-ksi-301-in-patients-with-wet-amd-dme-and-rvo/2477003/Kodiak Sciences announced promising safety, efficacy and durability data from its ongoing phase 1b study of its investigational therapy KSI-301 in patients with treatment-naïve wet age-related macular degeneration (AMD), diabetic macular edema (DME) and retinal vein
- Regenxbio Announces Additional Positive Interim Phase 1/2a Trial Update for RGX-314 for the Treatment of Wet AMDhttps://modernod.com/news/regenxbio-announces-additional-positive-interim-phase-1-2a-trial-update-for-rgx-314-for-the-treatment-of-wet-amd/2476995/Regenxbio announced interim data from the ongoing phase 1/2a trial of RGX-314 for the treatment of wet age-related macular degeneration (AMD). The results were presented by Jeffrey S. Heier, MD, Co-President and Director of Retina Research at Ophthalmic Consultants